Improved p38 MAPK Assay
Tech ID: 33796 / UC Case 2024-740-0
Background
The p38 mitogen activated protein kinase (p38 MAPK) when misregulated is implicated in a variety of human diseases and conditions including Alzheimer’s disease, Parkinson’s disease, HIV, cancer, and among many others. Identifying how p38 regulates different diseases ranging from cancer to Alzheimer’s can lead to improved compounds that can target a specific disease with less toxicity.
Brief Description
Professor Thomas Kuhlman and colleagues from the University of California, Riverside have developed a novel method named “Chemical Selectivity Readouts” and FRET sensor that can be used to identify new p38 MAPK inhibitors for development. Chemical Selectivity Readouts work by measuring p38 MAPK inhibition through the detection of resonance selectivity by Fourier transform. This technology is advantageous because it can enable the research and development of new and improved drugs targeting p38 MAPK for specific diseases like cancer and neurological disorders. Past clinical development roadblocks can be overcome with this new assay by developing more specific and less toxic drugs.
Applications
- For use in developing therapeutic treatments for human diseases and conditions including Alzheimer’s disease, Parkinson’s disease, HIV, and cancer.
Patent Status
Patent Pending
Related Materials
Contact
- Grace Yee
- grace.yee@ucr.edu
- tel: View Phone Number.
Other Information
Keywords
Resonance, resonance selectivity, chemical resonance, chemical resonance selectivity, p38 MAPK (mitogen activated protein kinase)
